Investor

TYK Medicines is positioned as an international innovative biotechnology company, based in China with a global presence. The company focuses on the research and development of tumor-targeting drugs, establishes in-depth cooperative relations with international leading scholars and research institutes in the field of new target development, and develops PROTAC technology. With highly scientific R&D technology as its core competitiveness and advanced compounds with the most commercial potential as its financial driving force, TYK Medicines aims at the drug development of "best-in-class", "first-tier-in-class", and "first-in-class". The company's mission is to bring together global drug development experts to work with patients to find the cure for the disease. The company is promoting two candidates in advanced clinical stages, which have BIC potential and address critical unmet medical needs for lung cancer and breast cancer patients.

Partnership

TYK Medicines, Inc. is an innovative biotechnology company founded by MNC veterans in 2017, focusing on the discovery of new-generation Kinase Inhibitors to address the unmet medical needs in cancer therapy. TYK medicines has a diversified pipeline with 10+ compounds including multiple phases from the PCC stage to Phase III clinical trial. The company is committed to providing patients with more effective and safer anti-tumor drugs. We are delighted and open to establishing extensive cooperation with potential partners to accelerate the development and commercialization of these projects globally. We look forward to communicating with you about the potential partnership.

Contact information